REFERENCES
- Colin PR. Interactions of high salt intake and the response of the cardiovascular system to aldosterone. Cardiology 2005; 13:118–124.
- Schmieder RE, Langenfeld MRW, Friedrich A, . I related to sodium excretion modulates left ventricular structure in human essential hypertension. Circulation 1996; 94:1304–1309.
- Williams JS, Williams GH, Jeunemaitre X, Hopkins PN, Conlin PR. Influence of dietary sodium on the renin–angiotansin–aldosterone system and prevalence of left ventricular hypertrophy by EKG criteria. J Hum Hypertens 2005; 19:133–138.
- Cailar G, Fesler P, Ribstein J, Mimran A. Dietary sodium, aldosterone, and left ventricular mass changes during long-term inhibition of the renin–angiotensin system. Hypertension 2010; 56:865–870.
- Cailar G, Ribstein J, Mimran A. Dietary sodium and target organ damage in essential hypertension. Am J Hypertens 2002; 15:222–229.
- Perry IJ, Beevers DG. Salt intake and stroke: a possible direct effect. J Hum Hypertens 1992; 6:23–25.
- Messerli FH, Schmieder RE, Weir MR. A perpetrator of hypertensive target organ disease? Arch Intern Med 1997; 157:2449–2452.
- Schmieder RE, Messerli FH, Garavaglia GE, Nunez BD. Dietary salt intake. A deterninant of cardiac involvement in essential hypertension. Circulation 1988; 78:951–956.
- Bragulat E, Sierra A. Salt intake, endothelial dysfunction, and salt-sensitive hypertension. J Clin Hypertens 2002; 4:41–46.
- Lahera V, Cachoferio V, Balfagon G, Rodicio JL. Aldosterone and its blockade: a cardiovascular and renal perspective. Sci World J 2006; 6:413–424.
- Kawano Y, Ando K, Matsuura H, . Report of working group for dietary salt reduction of the Japanese Society of Hypertension: (1) rationale for salt reduction and salt-restriction target level for the management of hypertension. Hypertens Res 2007; 30:879–886.
- Tochikubo O, Uneda S, Kaneko Y. Simple portable device for sampling a whole day’s urine and its application to hypertensive outpatients. Hypertension 1983; 5:270–274.
- Pimenta E, Gaddam KK, Oparil S, . Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension. Results from a randomized trial. Hypertension 2009; 54:475–481.
- Ubaid-Girioli S, Ferreira-Melo SE, Souza LA, . Aldosterone escape with diuretic or angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker combination therapy in patients with mild to moderate hypertension. J Clin Hypertens 2007; 9:770–774.
- Staessen J, Lijnen P, Fagard R, Verschueren LJ, Amery A. Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. J Endocr 1981; 91:457–465.
- Sato A, Saruta T. Aldosterone breakthrough during angiotensin-converting enzyme inhibitor therapy. Am J Hypertens 2003; 16:781–788.
- Sato A, Saruta T. Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy. J Intern Med 2001; 29:13–21.
- Bomback AS, Klemmer PJ. The incidence and implications of aldosterone breakthrough. Nephrology 2007; 3:486–492.
- Pitt B, Zannad F, Remme WJ, . The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1991; 341:709–717.
- Pitt B, Remme W, Zannad F, . Eplerenone, a selective aldosterone blockers, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348:1309–1321.
- Ohta Y, Tsuchihashi T, Onaka U, Miyata E. Long-term compliance of salt restriction and blood pressure control status in hypertensive outpatients. Clin Exp Hypertens 2010; 32:234–238.
- Ohta Y, Tsuchihashi T, Miyata E, Onaka U. Usefulness of self-monitoring of urinary salt excretion in hypertensive patients. Clin Exp Hypertens 2009; 31:690–697.
- Ohta Y, Tsuchihashi T, Onaka U, Eto K, Ueno M. Long-term compliance of salt restriction in Japanese hypertensive patients. Hypertens Res 2005; 28:953–957.